Sara Naji Rad1*, Behnam Rafiee2, Prachi Anand3, Marianne Frieri4
1Department of Medicine, Nassau University Medical Center, Hempstead Turnpike, East Meadow, NY 11554, USA.
2Deparment of Dermatology, Guilan University of Medical Sciences, Rasht, Iran.
3Division of Rheumatology, Department of Medicine, Nassau University Medical Center, Hempstead Turnpike, East Meadow, NY 11554, USA.
4Division of Allergy Immunology, Department of Medicine, Nassau University Medical Center, Hempstead Turnpike, East Meadow, NY 11554, USA.
Corresponding Author: Sara Naji Rad, Nassau University Medical Center, Department of Medicine, East Meadow, New York.
Tel: 516-572-6501; E-Mail: email@example.com
Received Date: 15 Jan 2017
Accepted Date: 07 Feb 2017
Published Date: 09 Feb 2017
Copyright © 2017 Naji Rad S
Citation: Naji Rad S, Rafiee B, Anand P and Frieri M. (2017). Diffuse Systemic Sclerosis: Evolution in Treatment. M J Immu. 1(1): 002.
Systemic sclerosis (SSc) is a chronic multisystem autoimmune disease with wide variety of clinical presentations which makes its treatment challenging for clinicians. The aim of therapy is to decrease disability and preventing life-threatening organ involvement. Treating patients at an early stage of diffuse systemic sclerosis with proper agents will improve outcomes if initiated before an inflammatory process becomes irreversible. Immunosuppressive therapies with D-penicillamine, methotrexate (MTX), cyclophosphamide and others have been used commonly as classic treatment. Deeper knowledge of the immunopathogenesis of SSc has initiated a new era in treatment of diffuse systemic sclerosis. One of the new areas is biologic therapy including rituximab, imatinib, fresolimumab and others. Studies in biologic therapy have revealed significant improvement among patients with diffuse systemic sclerosis. Also, over the last two decades another challenging area has been introduced with hematopoietic stem cell transplantation which might change the future of systemic sclerosis. This review emphasizes that there are still unmet needs to achieve effective treatment in diffuse SSc and to reach this goal more studies need to be conducted.
Diffuse Systemic Sclerosis; Scleroderma; Treatment.